MCID: MNT001
MIFTS: 72

Mantle Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Mantle Cell Lymphoma

MalaCards integrated aliases for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma 38 12 50 56 29 14
Lymphoma, Mantle Cell 50 13
Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse 69
Malignant Lymphoma - Lymphocytic, Intermediate Differentiation 69
Lymphoma, Mantle-Cell 42
Mantle Zone Lymphoma 56
Lymphoma Mantle-Cell 52
Lcm 56
Mcl 56

Characteristics:

Orphanet epidemiological data:

56
mantle cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (United States),1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050746
MeSH 42 D020522
Orphanet 56 ORPHA52416
MESH via Orphanet 43 D020522
UMLS via Orphanet 70 C0555202
ICD10 via Orphanet 34 C83.1
ICD10 33 C83.1

Summaries for Mantle Cell Lymphoma

NIH Rare Diseases : 50 mantle cell lymphoma (mcl) belongs to a group of diseases known as non-hodgkin’s lymphomas (nhl). nhl's are cancers that affect the the lymphatic system (part of the immune system). in mcl, there are cancerous b-cells (a type of immune system cell). the cancerous b-cells are within a region of the lymph node known as the mantle zone. although mcls are slow-growing cancers, the cancer is usually widespread by the time it is diagnosed. in these situations, treatment must be intensive since mcl can become life threatening within a short period of time. mcl accounts for 6% of all nhl's and is mostly found in males during their early 60s. last updated: 4/27/2016

MalaCards based summary : Mantle Cell Lymphoma, also known as lymphoma, mantle cell, is related to prostate cancer and follicular lymphoma, and has symptoms including splenomegaly, fatigue and fever. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Imbruvica and Revlimid have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Increased cell death HMECs cells and Increased viability with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

Wikipedia : 72 Mantle cell lymphoma (MCL) is a type of non-Hodgkin\'s lymphoma (NHL), comprising about 6% of NHL cases.... more...

Related Diseases for Mantle Cell Lymphoma

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
id Related Disease Score Top Affiliating Genes
1 prostate cancer 29.7 BCL2 CCND1 EZH2 MCL1 MDM2 MTOR
2 follicular lymphoma 11.4
3 lymphoma 11.2
4 lysosomal storage disease 11.0 BCL2 CCND1
5 chest wall lymphoma 11.0 ATM CCND1 TP53
6 raynaud disease 11.0 CCND1 CD5 SOX11
7 rnase t2-deficient leukoencephalopathy 11.0 MDM2 TP53
8 hip subluxation 10.9 BCL2 CCND1 TP53
9 bladder squamous cell carcinoma 10.9 CCND1 MDM2 TP53
10 hemoglobinemia 10.9 CCND1 MTOR MYC
11 biliary dyskinesia 10.9 ATM MDM2 TP53
12 oral antidiabetic drugs toxicity or dose selection 10.9 BCL2 CCND1 TP53
13 sparse hair ptosis mental retardation 10.9 BCL2 MDM2 TP53
14 acute cholinergic dysautonomia 10.9 MDM2 TP53
15 cleft lip palate dysmorphism kumar type 10.9 BCL2 CCND1 TP53
16 trigeminal nerve neoplasm 10.9 CD5 MME
17 progesterone-receptor positive breast cancer 10.9 CCND1 MTOR TP53
18 pneumonic plague 10.8 ATM CCND1 CD5 MYC
19 urethra adenocarcinoma 10.8 CCND1 MYC TP53
20 duodenal ulcer 10.8 ATM CD5 MYC TP53
21 medullomyoblastoma 10.8 CCND1 MYC TP53
22 mixed extragonadal germ cell cancer 10.8 BCL2 CCND1 MDM2 TP53
23 ovarian mesodermal adenosarcoma 10.8 BCL2 MME TP53
24 gangliosidosis gm1 10.8 MTOR MYC
25 trachea squamous cell carcinoma 10.8 CCND1 MYC TP53
26 nail disorder, nonsyndromic congenital, 1 10.8 BCL2 CCND1 MYC TP53
27 nasopharyngeal carcinoma 10.8 ATM BCL2 MDM2 TP53
28 hodgkin's lymphoma, mixed cellularity 10.8 BMI1 CCND1 TP53
29 villous adenoma 10.8 CCND1 MDM2 MYC TP53
30 gastric cancer, somatic 10.8 BCL2 CCND1 MYC TP53
31 pseudotyphus of california 10.8 BCL2 BCL6
32 pediatric lymphoma 10.8 BCL6 CD5 SOX11
33 bardet-biedl syndrome 10.8 CCND1 MYC TP53
34 alcoholic hepatitis 10.8 CCND2 PMAIP1 TP53
35 childhood spinal cord tumor 10.8 BCL6 CD5 TP53
36 pylorus cancer 10.8 BCL2 BCL6 TP53
37 esophagus lymphoma 10.7 CCND1 MDM2 MYC TP53
38 gallbladder cancer 10.7 CCND1 MYC TP53
39 vaccinia 10.7 BCL2 CD5
40 thrombocytopenia, anemia, and myelofibrosis 10.7 BCL2 BCL6 IGH
41 brown-vialetto-van laere syndrome 10.7 CCND1 MYC TP53
42 estrogen-receptor positive breast cancer 10.7 BCL6 CD5 MYC
43 small cell sarcoma 10.7 BCL2 CCND1 MDM2 MYC TP53
44 bagatelle cassidy syndrome 10.7 CD19 CD5 MYC TP53
45 post-surgical hypoinsulinemia 10.7 CCND1 CCND3 MDM2 MYC TP53
46 giant cell glioblastoma 10.7 CCND1 MDM2 MTOR MYC TP53
47 degenerative myopia 10.7 CD19 CD5 MME
48 cervical cancer, somatic 10.7 CCND1 EZH2 MDM2 TP53
49 glandular-alveolar pattern testicular yolk sac tumor 10.7 BCL2 CD5
50 gastric small cell carcinoma 10.6 BCL6 MME

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:



Diseases related to Mantle Cell Lymphoma

Symptoms & Phenotypes for Mantle Cell Lymphoma

Human phenotypes related to Mantle Cell Lymphoma:

56 32 (show all 9)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 56 32 frequent (33%) Frequent (79-30%) HP:0001744
2 fatigue 56 32 frequent (33%) Frequent (79-30%) HP:0012378
3 fever 56 32 frequent (33%) Frequent (79-30%) HP:0001945
4 lymphadenopathy 56 32 hallmark (90%) Very frequent (99-80%) HP:0002716
5 weight loss 56 32 frequent (33%) Frequent (79-30%) HP:0001824
6 anorexia 56 32 frequent (33%) Frequent (79-30%) HP:0002039
7 b-cell lymphoma 56 32 hallmark (90%) Very frequent (99-80%) HP:0012191
8 abnormality of the gastrointestinal tract 56 32 occasional (7.5%) Occasional (29-5%) HP:0011024
9 abnormality of bone marrow cell morphology 56 32 frequent (33%) Frequent (79-30%) HP:0005561

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.63 BCL6 BMI1 CCND2 MDM2 MYC TP53
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 ATM BCL2 MCL1 MDM2 PMAIP1 TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 BCL2 MCL1 TP53 ATM
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 BTK CCND1 MCL1 MYC TP53 ATM

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 ATM BCL2 BCL6 BTK CCND1 CCND2
2 cardiovascular system MP:0005385 10.37 ATM BCL2 BCL6 CCND1 CCND2 CCND3
3 cellular MP:0005384 10.36 BTK CCND1 CD19 EZH2 MCL1 MDM2
4 immune system MP:0005387 10.36 SOX11 TP53 ATM BCL2 BCL6 BTK
5 homeostasis/metabolism MP:0005376 10.33 CCND2 CCND3 CD19 EZH2 MDM2 MME
6 endocrine/exocrine gland MP:0005379 10.32 ATM BCL2 BCL6 CCND1 CCND2 CCND3
7 behavior/neurological MP:0005386 10.31 EZH2 MDM2 MTOR MYC TP53 ATM
8 growth/size/body region MP:0005378 10.31 ATM BCL2 BCL6 BTK CCND1 CCND3
9 integument MP:0010771 10.22 MYC SOX11 TP53 ATM BCL2 BTK
10 mortality/aging MP:0010768 10.2 BTK CCND1 CCND2 CCND3 CD19 EZH2
11 digestive/alimentary MP:0005381 10.14 BCL2 BTK CCND1 CD19 MDM2 MYC
12 embryo MP:0005380 10.13 ATM EZH2 MCL1 MDM2 MTOR MYC
13 liver/biliary system MP:0005370 9.97 BCL6 CCND2 CCND3 CD19 MDM2 MME
14 neoplasm MP:0002006 9.96 ATM BCL2 BTK CCND1 CCND3 CD19
15 nervous system MP:0003631 9.93 EZH2 MDM2 MTOR MYC SOX11 TP53
16 normal MP:0002873 9.73 CCND1 CCND3 CD19 CD5 EZH2 MCL1
17 reproductive system MP:0005389 9.28 ATM BCL2 BCL6 CCND1 CCND2 MCL1

Drugs & Therapeutics for Mantle Cell Lymphoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Imbruvica 17 46 IBRUTINIB Pharmacyclics November of 2013/February 2014
2
Revlimid 17 46 LENALIDOMIDE Celgene June 2013
3
Velcade 17 46 BORTEZOMIB Millennium Pharmaceuticals May 2003

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 498)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
4
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
5
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
6
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
8
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
10 Thiotepa Approved Phase 4,Phase 2,Phase 3,Phase 1 52-24-4 5453
11
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
12
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
13
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
14
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
15
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
16 Dexamethasone acetate Phase 4,Phase 3,Phase 1,Phase 2 1177-87-3
17 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
19
protease inhibitors Phase 4,Phase 3,Phase 1,Phase 2
20 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
21 HIV Protease Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
22 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
24 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
25 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
26 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
29 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
30 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
31 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
34 Antiemetics Phase 4,Phase 3,Phase 1,Phase 2
35 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
37 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
38 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
39 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2
40 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
41 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
42 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
45 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
47
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
48
Idarubicin Approved Phase 3 58957-92-9 42890
49
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
50
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612

Interventional clinical trials:

(show top 50) (show all 953)

id Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 EDOCH Alternating With DHAP for New Diagnosed Younger MCL Recruiting NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
3 An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Active, not recruiting NCT01833039 Phase 4 Ibrutinib
4 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Active, not recruiting NCT01180049 Phase 4 temsirolimus;temsirolimus
5 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Not yet recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
6 Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma Unknown status NCT00016887 Phase 3 carmustine;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan
7 Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma Unknown status NCT00641095 Phase 3 cyclophosphamide;fludarabine phosphate
8 Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL Unknown status NCT00209222 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Cisplatinum;Ara-C;Dexamethasone;BCNU;Melphalan;Etoposide;G-CSF
9 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
10 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
11 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
12 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
13 Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
14 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
15 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
16 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
17 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
18 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
19 Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Completed NCT01646021 Phase 3 Ibrutinib;Temsirolimus
20 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma Completed NCT00722137 Phase 3 Rituximab 375 mg/m^2;Cyclophosphamide 750 mg/m^2;Doxorubicin 50 mg/m^2;VELCADE 1.3 mg/m^2;Prednisone 100 mg/m^2;Vincristine 1.4 mg/m^2
21 Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study Completed NCT00877006 Phase 3 bendamustine;rituximab;vincristine;prednisone;cyclophosphamide;doxorubicin
22 Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma Completed NCT00003280 Phase 3
23 Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed NCT01073163 Phase 3 Bendamustine;Rituximab
24 Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) Completed NCT00117598 Phase 3 Temsirolimus (CCI-779);Temsirolimus (CCI-779);Investigator's choice
25 Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab Completed NCT01456351 Phase 3 Bendamustine plus Rituximab;Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
26 Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Completed NCT00921414 Phase 3 Rituximab
27 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3 Bendamustine;Standard chemotherapy CHOP + Ritiximab
28 A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma Completed NCT00269113 Phase 3 rituximab [MabThera/Rituxan];Standard chemotherapy
29 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
30 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
31 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
32 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
33 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
34 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
35 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
36 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
37 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
38 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
39 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
40 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
41 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
42 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
43 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
44 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
45 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
46 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
47 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
48 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
49 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
50 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir

Search NIH Clinical Center for Mantle Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, mantle-cell

Genetic Tests for Mantle Cell Lymphoma

Genetic tests related to Mantle Cell Lymphoma:

id Genetic test Affiliating Genes
1 Mantle Cell Lymphoma 29

Anatomical Context for Mantle Cell Lymphoma

MalaCards organs/tissues related to Mantle Cell Lymphoma:

39
B Cells, Bone, Bone Marrow, T Cells, Liver, Kidney, Breast

Publications for Mantle Cell Lymphoma

Articles related to Mantle Cell Lymphoma:

(show top 50) (show all 1044)
id Title Authors Year
1
The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma. ( 28503306 )
2017
2
Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma. ( 28860327 )
2017
3
Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission. ( 28828884 )
2017
4
Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. ( 28388555 )
2017
5
The BTK inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on the NF-I_B mutational status. ( 28838994 )
2017
6
Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence. ( 28457696 )
2017
7
Gastrointestinal mantle cell lymphoma with isolated mass and multiple lymphomatous polyposis: report of two cases. ( 28451951 )
2017
8
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ( 28881919 )
2017
9
Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma. ( 28910460 )
2017
10
Maintenance Rituximab after High-Dose Therapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma. ( 28939452 )
2017
11
Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. ( 28404221 )
2017
12
SOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma. ( 28429312 )
2017
13
Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi. ( 28082342 )
2017
14
Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma. ( 28466437 )
2017
15
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. ( 28040733 )
2017
16
Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis. ( 28529032 )
2017
17
Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients. ( 27776009 )
2017
18
The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma. ( 28905990 )
2017
19
The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/I^a89catenin pathway and DNA methyltransferase-1. ( 28901456 )
2017
20
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. ( 28055107 )
2017
21
Mantle Cell Lymphoma Presenting as a Subcutaneous Soft Tissue Mass With an Unusual Appearance. ( 28081018 )
2017
22
Reproducibility of SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients. ( 27720733 )
2017
23
Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia. ( 28592433 )
2017
24
The potential for chemotherapy-free strategies in mantle cell lymphoma. ( 28899853 )
2017
25
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. ( 28832957 )
2017
26
Cyclin D1-negative mantle cell lymphoma with aberrant CD3 expression. ( 28912297 )
2017
27
First reported case of disseminated Nocardia kroppenstedtii sp nov. infection presenting with brain abscess and endocarditis in an immunocompromised patient with mantle cell lymphoma: challenges in diagnosis and treatment. ( 28062425 )
2017
28
Expression of LEF1 in mantle cell lymphoma. ( 28038713 )
2017
29
Incidence and survival trends in mantle cell lymphoma. ( 28444739 )
2017
30
Mantle cell lymphoma with central nervous system involvement simulating bilateral subdural hematomas. ( 28063897 )
2017
31
Novel agents in mantle cell lymphoma. ( 28480764 )
2017
32
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. ( 28408615 )
2017
33
Correction: ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy. ( 28373366 )
2017
34
Orbital mantle cell lymphoma presenting as myasthenia gravis. ( 28820310 )
2017
35
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. ( 28416797 )
2017
36
Case Study: Rare Case of Mantle Cell Lymphoma With Extranodal Involvement in the Foot. ( 28842094 )
2017
37
SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity-reply. ( 28461033 )
2017
38
Mantle Cell Lymphoma Presenting with Acute Bilateral Ophthalmoplegia. ( 28845330 )
2017
39
Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). ( 28911068 )
2017
40
Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications. ( 28115200 )
2017
41
SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity. ( 28457728 )
2017
42
Persistence of a t(11;14)-positive clone in a patient with mantle cell lymphoma for 20A years. ( 28396772 )
2017
43
Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology. ( 28495928 )
2017
44
Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue. ( 28434928 )
2017
45
Anchimerically Activated ProTides as Inhibitors of Cap-Dependent Translation and Inducers of Chemosensitization in Mantle Cell Lymphoma. ( 28858511 )
2017
46
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. ( 28066928 )
2017
47
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. ( 28533307 )
2017
48
Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia. ( 28473415 )
2017
49
Autologous hematopoietic cell transplantation of mantle cell lymphoma: emerging trends. ( 28832354 )
2017
50
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. ( 28953447 )
2017

Variations for Mantle Cell Lymphoma

ClinVar genetic disease variations for Mantle Cell Lymphoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 ATM NM_000051.3(ATM): c.7268A> G (p.Glu2423Gly) single nucleotide variant Pathogenic rs121434221 GRCh37 Chromosome 11, 108199926: 108199926
2 ATM NM_000051.3(ATM): c.7251_7253dupGAA (p.Lys2418_Arg2419insLys) duplication Pathogenic rs796051857 GRCh38 Chromosome 11, 108329182: 108329184
3 ATM NM_000051.3(ATM): c.4081C> T (p.Gln1361Ter) single nucleotide variant Pathogenic rs121434222 GRCh37 Chromosome 11, 108158414: 108158414

Cosmic variations for Mantle Cell Lymphoma:

9 (show top 50) (show all 318)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM3733325 ZNF296 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.488G>A p.G163D 6
2 COSM3733324 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.6190G>A p.E2064K 6
3 COSM3733267 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.8147C>G p.S2716* 6
4 COSM10662 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.743G>A p.R248Q 6
5 COSM6901 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.559+1G>A p.? 6
6 COSM44687 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.379T>C p.S127P 6
7 COSM44972 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.831T>A p.C277* 6
8 COSM43846 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.487T>C p.Y163H 6
9 COSM10786 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.949C>T p.Q317* 6
10 COSM10883 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.731G>A p.G244D 6
11 COSM11114 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.528C>G p.C176W 6
12 COSM11450 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.644G>T p.S215I 6
13 COSM10758 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.659A>G p.Y220C 6
14 COSM44309 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.440T>G p.V147G 6
15 COSM10749 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.830G>T p.C277F 6
16 COSM10659 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.817C>T p.R273C 6
17 COSM43651 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.763A>T p.I255F 6
18 COSM43826 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.706T>A p.Y236N 6
19 COSM43814 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.587G>C p.R196P 6
20 COSM10724 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.839G>C p.R280T 6
21 COSM10648 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.524G>A p.R175H 6
22 COSM10705 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.586C>T p.R196* 6
23 COSM44467 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.497C>G p.S166* 6
24 COSM11089 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.584T>C p.I195T 6
25 COSM10656 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.742C>T p.R248W 6
26 COSM44962 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.774A>T p.E258D 6
27 COSM11123 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.838A>G p.R280G 6
28 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.581T>G p.L194R 6
29 COSM10660 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.818G>A p.R273H 6
30 COSM10667 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.646G>A p.V216M 6
31 COSM3733439 SMC1A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2398C>G p.Q800E 6
32 COSM3733438 SMC1A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2400G>T p.Q800H 6
33 COSM3733301 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2641G>A p.D881N 6
34 COSM3733382 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3109A>T p.N1037Y 6
35 COSM3733287 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.4600C>A p.Q1534K 6
36 COSM3733280 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3724G>T p.E1242* 6
37 COSM3733500 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3565C>G p.R1189G 6
38 COSM3733331 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2897G>A p.R966Q 6
39 COSM3733266 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3186C>G p.H1062Q 6
40 COSM3733321 SI haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1126C>T p.R376W 6
41 COSM3733285 SI haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1825T>C p.W609R 6
42 COSM3733430 SALL3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3044C>T p.S1015F 6
43 COSM3733372 ROBO2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2083C>T p.R695* 6
44 COSM3733347 ROBO2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.964G>A p.D322N 6
45 COSM3733293 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2570G>T p.R857L 6
46 COSM3733320 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.52G>A p.A18T 6
47 COSM3733492 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1535T>A p.L512* 6
48 COSM171725 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.838G>T p.E280* 6
49 COSM363436 POT1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.803G>A p.G268D 6
50 COSM3733311 POT1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.131G>A p.C44Y 6

Copy number variations for Mantle Cell Lymphoma from CNVD:

7 (show all 39)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 44978 10 6600000 12200000 Loss Mantle cell lymphoma
2 49103 11 102900000 110400000 Loss ACAT Mantle cell lymphoma
3 49104 11 102900000 110400000 Loss ATM Mantle cell lymphoma
4 49105 11 102900000 110400000 Loss CUL5 Mantle cell lymphoma
5 49106 11 102900000 110400000 Loss FDX1 Mantle cell lymphoma
6 49107 11 102900000 110400000 Loss NPAT Mantle cell lymphoma
7 49108 11 102900000 110400000 Loss RAB39 Mantle cell lymphoma
8 49703 11 110400000 112500000 Loss Mantle cell lymphoma
9 49990 11 112500000 114500000 Loss TMPRSS5 Mantle cell lymphoma
10 49991 11 112500000 114500000 Loss USP28 Mantle cell lymphoma
11 49992 11 112500000 114500000 Loss ZW10 Mantle cell lymphoma
12 54401 11 43500000 48800000 Loss TP53I11 Mantle cell lymphoma
13 60881 11 92800000 97200000 Loss MAML2 Mantle cell lymphoma
14 61262 11 97200000 102100000 Loss BIRC2 Mantle cell lymphoma
15 61263 11 97200000 102100000 Loss BIRC3 Mantle cell lymphoma
16 74176 13 101700000 104800000 Loss BIVM Mantle cell lymphoma
17 74177 13 101700000 104800000 Loss ERCC5 Mantle cell lymphoma
18 74178 13 101700000 104800000 Loss KDELC1 Mantle cell lymphoma
19 74694 13 110300000 115169878 Loss C13orf11 Mantle cell lymphoma
20 74695 13 110300000 115169878 Loss C13orf17 Mantle cell lymphoma
21 74696 13 110300000 115169878 Loss CUL4A Mantle cell lymphoma
22 74697 13 110300000 115169878 Loss GRTP1 Mantle cell lymphoma
23 74698 3 117011831 117647068 Loss LAMP Mantle cell lymphoma
24 74699 13 110300000 115169878 Loss TFDP1 Mantle cell lymphoma
25 77990 13 48877883 49056026 Deletion RB1 Mantle cell lymphoma
26 79883 13 79000000 95000000 Copy number miR-17-92 Mantle cell lymphoma
27 80925 13 99300000 101700000 Loss PCCA Mantle cell lymphoma
28 118115 17 7571720 7590868 Mutation P53 Mantle cell lymphoma
29 141432 2 210288771 210598834 Deletion MAP2 Mantle cell lymphoma
30 143512 2 237300000 243199373 Loss Mantle cell lymphoma
31 170852 3 160700000 167600000 Loss SLITRK3 Mantle cell lymphoma
32 245172 9 102600000 108200000 Loss INVS Mantle cell lymphoma
33 248837 9 137400000 141213431 Loss TRAF2 Mantle cell lymphoma
34 250734 9 21967751 21994490 Deletion CDKN2A Mantle cell lymphoma
35 252714 9 36300000 38400000 Loss MELK Mantle cell lymphoma
36 254747 9 68700000 72200000 Loss TJP2 Mantle cell lymphoma
37 256309 9 91800000 93900000 Loss DIRAS2 Mantle cell lymphoma
38 256992 9 99300000 102600000 Loss GPR51 Mantle cell lymphoma
39 256993 9 99300000 102600000 Loss TBC1D2 Mantle cell lymphoma

Expression for Mantle Cell Lymphoma

Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Pathways for Mantle Cell Lymphoma

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 87)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 ATM BCL2 BTK CCND1 CCND2 CCND3
2
Show member pathways
13.48 BCL2 BTK CCND1 CCND2 CCND3 MDM2
3
Show member pathways
13.28 BCL2 BTK CCND1 CD19 MTOR MYC
4
Show member pathways
13.04 ATM BCL6 MDM2 MTOR PMAIP1 TP53
5
Show member pathways
12.92 ATM BCL2 MCL1 MDM2 MYC PMAIP1
6
Show member pathways
12.79 BTK CD19 MDM2 MTOR TP53
7 12.76 BCL2 CCND1 MDM2 MTOR MYC TP53
8
Show member pathways
12.73 ATM CCND1 MDM2 MYC TP53
9
Show member pathways
12.66 BCL2 BCL6 CCND1 MTOR MYC
10
Show member pathways
12.66 ATM CCND1 CCND2 CCND3 MDM2 MYC
11 12.64 ATM BCL2 CCND1 CCND2 CCND3 CD19
12
Show member pathways
12.63 CCND1 CCND2 CCND3 MYC TP53
13
Show member pathways
12.63 ATM BCL2 CCND1 CCND2 MDM2 MTOR
14 12.6 ATM CCND1 CCND2 CCND3 MDM2 TP53
15
Show member pathways
12.57 BCL2 CCND1 CCND2 MTOR MYC
16
Show member pathways
12.56 MDM2 MTOR MYC TP53
17
Show member pathways
12.53 ATM BCL2 MDM2 MTOR TP53
18 12.53 ATM CCND1 CCND2 CCND3 MYC TP53
19 12.51 CCND1 CCND2 CCND3 MYC TP53
20 12.46 ATM CCND1 CCND2 CCND3 MDM2 MYC
21
Show member pathways
12.45 ATM CCND1 CCND2 CCND3 TP53
22
Show member pathways
12.44 BCL6 BTK CD19 MYC
23
Show member pathways
12.42 CCND1 CCND2 CCND3 IGH MDM2 MTOR
24
Show member pathways
12.41 CCND1 MDM2 MTOR MYC TP53
25 12.4 CCND1 CCND2 CCND3 MDM2 PMAIP1 TP53
26
Show member pathways
12.39 BCL6 BTK CD19 MTOR
27 12.39 BCL2 CD19 MDM2 MYC TP53
28 12.39 CCND1 MDM2 MTOR MYC TP53
29
Show member pathways
12.37 ATM CCND1 CCND2 CCND3 MDM2 MYC
30
Show member pathways
12.35 ATM BCL2 CCND1 MDM2 TP53
31 12.32 ATM BCL6 BMI1 CCND2 MDM2 MYC
32 12.31 BCL2 MCL1 MYC PMAIP1
33
Show member pathways
12.29 CCND1 CCND2 CCND3 MYC
34
Show member pathways
12.29 BCL2 CCND1 CCND2 CCND3 MCL1 MTOR
35
Show member pathways
12.29 BCL2 CCND1 CCND2 CCND3 MDM2 MTOR
36 12.25 CCND1 CCND2 MYC TP53
37 12.21 CCND1 CCND2 CCND3 MYC
38
Show member pathways
12.19 ATM BCL6 CCND1 CCND2 MDM2
39 12.19 ATM BCL2 CCND1 MDM2 MTOR MYC
40 12.17 BCL2 BCL6 MCL1 MDM2 PMAIP1 TP53
41 12.17 ATM BCL2 BMI1 CCND1 CCND2 EZH2
42
Show member pathways
12.15 BCL2 BTK CCND2 MYC
43 12.12 ATM BCL2 MDM2 TP53
44 12.1 CCND1 MDM2 MTOR MYC TP53
45 12.08 CCND1 MDM2 MTOR MYC TP53
46 12.08 BCL2 BCL6 CCND1 MCL1 MYC TP53
47 12.06 BCL2 BMI1 MDM2 MTOR TP53
48
Show member pathways
12.04 ATM BCL6 PMAIP1 TP53
49 11.95 CCND1 CCND3 MDM2 MYC TP53
50 11.94 ATM BCL2 CCND1 CCND2 CCND3 MDM2

GO Terms for Mantle Cell Lymphoma

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrial outer membrane GO:0005741 9.56 BCL2 MCL1 MTOR PMAIP1
2 nucleoplasm GO:0005654 9.44 ATM BCL2 BCL6 BMI1 CCND1 CCND2
3 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.13 CCND1 CCND2 CCND3
4 nucleus GO:0005634 10.06 ATM BCL2 BCL6 BMI1 BTK CCND1

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 40)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.98 BCL2 BCL6 CCND2 MCL1 MDM2 MYC
2 regulation of cell proliferation GO:0042127 9.95 BCL6 BTK CCND3 EZH2
3 positive regulation of protein phosphorylation GO:0001934 9.92 CCND1 CCND2 CCND3 MTOR
4 cell cycle arrest GO:0007050 9.92 ATM MTOR MYC TP53
5 regulation of gene expression GO:0010468 9.88 BCL2 BMI1 EZH2 MDM2 MYC
6 post-embryonic development GO:0009791 9.85 ATM BCL2 MTOR
7 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.82 ATM MDM2 TP53
8 regulation of apoptotic process GO:0042981 9.8 ATM BCL2 BCL6 MCL1 PMAIP1 TP53
9 negative regulation of autophagy GO:0010507 9.78 BCL2 MCL1 MTOR
10 cellular response to organic substance GO:0071310 9.77 BCL2 CCND1 MDM2
11 cellular response to glucose starvation GO:0042149 9.77 BCL2 PMAIP1 TP53
12 response to steroid hormone GO:0048545 9.75 BCL2 CCND1 MDM2
13 response to gamma radiation GO:0010332 9.74 BCL2 MYC TP53
14 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.73 BCL2 PMAIP1 TP53
15 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.71 BCL2 PMAIP1 TP53
16 cell aging GO:0007569 9.7 BCL2 MTOR TP53
17 cellular response to DNA damage stimulus GO:0006974 9.7 ATM BCL2 BCL6 CCND1 MYC PMAIP1
18 cellular response to gamma radiation GO:0071480 9.69 ATM MDM2 TP53
19 determination of adult lifespan GO:0008340 9.68 ATM TP53
20 response to magnesium ion GO:0032026 9.68 CCND1 MDM2
21 growth GO:0040007 9.68 BCL2 MTOR
22 oocyte development GO:0048599 9.67 ATM BCL2
23 positive regulation of DNA damage response, signal transduction by p53 class mediator GO:0043517 9.67 ATM PMAIP1
24 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.67 CCND1 CCND2 CCND3
25 positive regulation of histone deacetylation GO:0031065 9.66 BCL6 TP53
26 cellular response to X-ray GO:0071481 9.65 ATM CCND2
27 mitotic G1 DNA damage checkpoint GO:0031571 9.65 CCND1 TP53
28 regulation of cell cycle GO:0051726 9.65 ATM BCL2 CCND1 CCND2 CCND3
29 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.63 ATM MCL1
30 response to iron ion GO:0010039 9.63 BCL2 CCND1 MDM2
31 positive regulation of neuron maturation GO:0014042 9.61 BCL2 MTOR
32 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.61 BCL6 BMI1 CCND1 CCND3 EZH2 MDM2
33 replicative senescence GO:0090399 9.58 ATM MME TP53
34 cellular response to actinomycin D GO:0072717 9.55 MDM2 TP53
35 regulation of mitochondrial membrane permeability GO:0046902 9.54 BCL2 PMAIP1 TP53
36 positive regulation of response to DNA damage stimulus GO:2001022 9.36 MYC
37 cellular response to hypoxia GO:0071456 9.1 BCL2 MDM2 MTOR MYC PMAIP1 TP53
38 apoptotic process GO:0006915 10.11 ATM BCL2 BTK MCL1 PMAIP1 TP53
39 positive regulation of cell proliferation GO:0008284 10.06 BCL2 CCND1 CCND2 MDM2 MYC SOX11
40 positive regulation of gene expression GO:0010628 10.03 MDM2 MTOR MYC SOX11 TP53

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 ATM BCL2 BCL6 BMI1 BTK CCND1
2 protein kinase binding GO:0019901 9.55 CCND1 CCND2 CCND3 MTOR TP53
3 BH3 domain binding GO:0051434 8.96 BCL2 MCL1

Sources for Mantle Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....